Thursday, June 30, 2011

Sorbent Therapeutics Gains $36M

Sunnyvale-based Sorbent Therapeutics, a biopharmaceuticals firm targeting the cardiovascular and renal disease area, has raised $36M in a Series B financing round. The firm said the funding was led by Novartis Venture Funds, and includes existing investors Sofinnova Ventures, ARCH Venture Partners, CMEA Capital and AgeChem. The firm said the new round ups the company's Series B to a total of $53M. More information »